tbuckley/cabot-search huggingface dataset:
Muscle Oxygen Supply and Use in Type 1 Diabetes, From Ambient Air to the Mitochondrial Respiratory Chain: Is There a Limiting Step?
Authors: Elsa Heyman, Frédéric Daussin, Valerie Wieczorek, Robert Caiazzo, Régis Matran, Phanélie Berthon, Julien Aucouturier, Serge Berthoin, Aurélien Descatoire, Erwan Leclair, Gaëlle Marais, Adrien Combes, Pierre Fontaine, Sémah Tagougui
Journal: Diabetes Care (2019)

Long before clinical complications of type 1 diabetes (T1D) develop, oxygen supply and use can be altered during activities of daily life. We examined in patients with uncomplicated T1D all steps of the oxygen pathway, from the lungs to the mitochondria, using an integrative ex vivo (muscle biopsies) and in vivo (during exercise) approach.We compared 16 adults with T1D with 16 strictly matched healthy control subjects. We assessed lung diffusion capacity for carbon monoxide and nitric oxide, exercise-induced changes in arterial O2 content (SaO2, PaO2, hemoglobin), muscle blood volume, and O2 extraction (via near-infrared spectroscopy). We analyzed blood samples for metabolic and hormonal vasoactive moieties and factors that are able to shift the O2-hemoglobin dissociation curve. Mitochondrial oxidative capacities were assessed in permeabilized vastus lateralis muscle fibers.Lung diffusion capacity and arterial O2 transport were normal in patients with T1D. However, those patients displayed blunted exercise-induced increases in muscle blood volume, despite higher serum insulin, and in O2 extraction, despite higher erythrocyte 2,3-diphosphoglycerate. Although complex I- and complex II-supported mitochondrial respirations were unaltered, complex IV capacity (relative to complex I capacity) was impaired in patients with T1D, and this was even more apparent in those with long-standing diabetes and high HbA1c. [Formula: see text]O2max was lower in patients with T1D than in the control subjects.Early defects in microvascular delivery of blood to skeletal muscle and in complex IV capacity in the mitochondrial respiratory chain may negatively impact aerobic fitness. These findings are clinically relevant considering the main role of skeletal muscle oxidation in whole-body glucose disposal.
P1.01-72 A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
Authors: M. Krebs, P. Brunsvig, Å. Helland, N. Viñolas, S. Aix, E. Carcereny, M. Dómine Gomez, J.M. Trigo Perez, E. Arriola, R. Garcia Campelo, J. Spicer, J. Thompson, A.L. Ortega Granados, R. Holt, D. Smethurst, J. Lorens, M. Shoaib, A. Siddiqui, J. Schoelermann, K. Lorens, E. Schmidt, M.J. Chisamore, E. Felip
Journal: Journal of Thoracic Oncology (2019)
P2.14-52 The Results from Plasma EGFR Mutation Analysis in NEJ026 Study
Authors: T. Fukuhara, H. Saito, N. Furuya, K. Watanabe, S. Sugawara, S. Iwasawa, Y. Tsunezuka, O. Yamaguchi, M. Okada, K. Yoshimori, I. Nakachi, A. Gemma, K. Azuma, F. Kurimoto, Y. Tsubata, Y. Fujita, H. Nagashima, G. Asai, S. Watanabe, M. Miyazaki, K. Hagiwara, T. Nukiwa, S. Morita, K. Kobayashi, M. Maemondo
Journal: Journal of Thoracic Oncology (2019)
EP1.14-49 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Exploratory Biomarker Analysis
Authors: J. Wang, J. Zhao, H. Bai, X. Wang, Y. Wang, J. Duan, H. Chen, Z. Xue, S. Meng, Y. Tian, A. Cseh, D.C. Huang, Y. Wu
Journal: Journal of Thoracic Oncology (2019)
P2.01-10 Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study
Authors: J. De Castro Carpeno, E. Felip, O. Juan, R. Garcia Campelo, D. Aguiar, J. Terrassa, R. Lopez Castro, A. Calles Blanco, A. Paredes, R. Bernabe, I. Barneto, J. Campillo, L. García-Palacios, F. Rojo
Journal: Journal of Thoracic Oncology (2019)
P2.06-05 Multimodality Therapy Using Total Pleurectomy in Malignant Pleural Mesothelioma: Long-Term Outcomes in 150 Consecutive Cases
Authors: L. Lang-Lazdunski, Y.Z. Zhang, S. Popat, M. O'Brien, J. Steele, T. Newsom-Davis, R. Lal, A. Nicholson
Journal: Journal of Thoracic Oncology (2019)
Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
Authors: Dora Pinto, Craig Fenwick, Christophe Caillat, Chiara Silacci, Serafima Guseva, François Dehez, Christophe Chipot, Sonia Barbieri, Andrea Minola, David Jarrossay, Georgia D. Tomaras, Xiaoying Shen, Agostino Riva, Maciej Tarkowski, Olivier Schwartz, Timothée Bruel, Jérémy Dufloo, Michael S. Seaman, David C. Montefiori, Antonio Lanzavecchia, Davide Corti, Giuseppe Pantaleo, Winfried Weissenhorn
Journal: Cell Host & Microbe (2019)

Highlights•bNAb LN01 neutralizes 92% of a 118-strain virus panel•LN01 targets the HIV-1 gp41 MPER, the TM region, and lipids•LN01-complexed MPER forms a continuous helix with TM•Most LN01 paratope residues interacting with MPER-TM and lipids are germline encodedSummaryPotent and broadly neutralizing antibodies (bnAbs) are the hallmark of HIV-1 protection by vaccination. The membrane-proximal external region (MPER) of the HIV-1 gp41 fusion protein is targeted by the most broadly reactive HIV-1 neutralizing antibodies. Here, we examine the structural and molecular mechansims of neutralization by anti-MPER bnAb, LN01, which was isolated from lymph-node-derived germinal center B cells of an elite controller and exhibits broad neutralization breadth. LN01 engages both MPER and the transmembrane (TM) region, which together form a continuous helix in complex with LN01. The tilted TM orientation allows LN01 to interact simultaneously with the peptidic component of the MPER epitope and membrane via two specific lipid binding sites of the antibody paratope. Although LN01 carries a high load of somatic mutations, most key residues interacting with the MPER epitope and lipids are germline encoded, lending support for the LN01 epitope as a candidate for lineage-based vaccine development.Graphical abstract
P2.09-19 Effect of Neoadjuvant (Radio)chemotherapy on PD-L1 Expression in Resected Non-Small Cell Lung Cancers
Authors: P. Zens, C. Bello, A. Scherz, A. Ochsenbein, M. Von Gunten, R. Schmid, C. Neppl, S. Berezowska
Journal: Journal of Thoracic Oncology (2019)
P2.04-16 Novel CT Based Radiomic Features are Prognostic and Predictive of Benefit of Chemoimmunotherapy in Advanced Non-Squamous NSCLC
Authors: P. Patil, M. Khorrami, A. Zagouras, K. Bera, P. Fu, A. Gupta, V. Velcheti, N. Pennell, A. Madabhushi
Journal: Journal of Thoracic Oncology (2019)
P2.09-23 PD-L1 Expression of Paired Primary Resected Non Small Cell Carcinoma and Metastatic Lymph Node Fine Needle Aspirates
Authors: A.M. Quinn, R. Bowden, A. Moss, R. Bloor, C. Harreld, C. Mcnulty, A. Montero, P. Crosbie, F. Blackhall, Y. Summers
Journal: Journal of Thoracic Oncology (2019)
EP1.01-41 Feasibility of EBUS-TBNA Cytologies for an Extensive Assessment of Predictive Biomarkers in Lung Cancer
Authors: R. Martin-Deleon, C. Teixido, R. Reyes, C. Cabrera, A. Fontana, S. Castillo, R.M. Marrades, N. Viñolas, D. Martinez, J. Ramirez, I. Vollmer, P. Jares, C.M. Lucena, N. Reguart, C. Agusti
Journal: Journal of Thoracic Oncology (2019)
EP1.15-26 Cardio Mediastinal Tumors - Diagnosis and Treatment in Two of Our Cases
Authors: F. Gradica, L. Lisha, D. Argjiri, A. Cani, F. Kokici, E. Prifti, A. Pere, F. Gradica, D. Lala, D. Xhemalaj, G. Quadir
Journal: Journal of Thoracic Oncology (2019)
P2.13-02 Persistent Occult Micrometastases in Mediastinal Lymph Nodes Are Associated with Reduced Survival After Neoadjuvant Therapy
Authors: P. Gwóźdź, M. Pasieka-Lis, K. Kołodziej, K. Solarczyk-Bombik, J. Pankowski, M. Zielinski
Journal: Journal of Thoracic Oncology (2019)
EP1.12-16 CD47 Expression and Prognosis in Patients with Small Cell Lung CancerCD47 Expression and Prognosis in Patients with Small Cell Lung Cancer
Authors: N. Hernandez-Pedro, M. Orozco-Morales, A. Aviles-Salas, L. Cabrera-Miranda, L. Ramírez-Tirado, P. Barrios -Bernal, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
MA14.10 Clinical Outcomes in Metastatic Squamous Lung Cancer with Targetable Driver Alterations
Authors: W. Lewis, G. Simon, F. Mott, V. Papadimitrakopoulou, W. Rinsurongkawong, J. Lewis, J. Lee, J. Roth, S. Swisher, J. Heymach, J. Zhang, V. Lam
Journal: Journal of Thoracic Oncology (2019)
The Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Pediatric Patients: A Ten-Year Experience from 1997 to 2007.
Authors: Ampaiwan Chuansumrit, Sumate Teeraratkul, Suporn Tripongkaruna, Suthep Wanichkul, Nongnuch Sirachainan, Samart Pakakasama, Pracha Nuntnarumit, Suradej Hongeng
Journal: Blood (2007)
P2.05-19 The Patency of Right Upper Lobe Bronchus After Y-Stent Placement Affect Outcome on Malignant Tracheobronchial Stenosis
Authors: S. Mizuguchi, M. Takahama, R. Nakajima, N. Nomura, S. Suzuki, Y. Kanno, R. Yamamoto
Journal: Journal of Thoracic Oncology (2019)
P2.18-04 Improved Outcome in Female Stage III NSCLC Diagnoses Is Driven by Non-Curative Intent Treatment, and Adenocarcinoma Histology
Authors: N. Alsaadoun, A. Gibson, F. Hao, M. Dean, A. Elegbede, S. Otsuka, R. Tudor, G. Bebb
Journal: Journal of Thoracic Oncology (2019)
Provision of postpartum care to women giving birth in health facilities in sub-Saharan Africa: A cross-sectional study using Demographic and Health Survey data from 33 countries
Authors: Lenka Benova, Onikepe Owolabi, Emma Radovich, Kerry L. M. Wong, David Macleod, Etienne V. Langlois, Oona M. R. Campbell
Journal: PLoS Medicine (2019)

Postpartum care has the potential to avert a substantial proportion of maternal and perinatal mortality and morbidity. There is a crucial gap in understanding the quality of postpartum care for women giving birth in health facilities in low- and middle-income settings. This is particularly the case in sub-Saharan Africa (SSA), where the levels of maternal and neonatal mortality are highest globally despite rapid increases in facility-based childbirth. This study estimated the percentage of women receiving a postpartum health check following childbirth in a health facility in SSA and examined the determinants of receiving such check.We used the most recent Demographic and Health Survey (DHS) conducted in 33 SSA countries between 2000-2016. We estimated the percentage of women receiving a postpartum check by a health professional while in the childbirth facility and the associated 95% confidence interval (CI) for each country. We analyzed determinants of receiving such checks using logistic regression of the pooled data. The analysis sample included 137,218 women whose most recent live birth in the 5- year period before the survey took place in a health facility. Of this pooled sample, 65.7% of women were under 30 years of age, 85.9% were currently married, and 57% resided in rural areas. Across countries, the median percentage of women who reported receiving a check was 71.7%, ranging from 26.6% in Eswatini (Swaziland) to 94.4% in Burkina Faso. The most fully adjusted model showed that factors from all four conceptual categories (obstetric/neonatal risk factors, care environment, and women's sociodemographic and child-related characteristics) were significant determinants of receiving a check. Women with a cesarean section had a significantly higher adjusted odds ratio (aOR) of 1.88 (95% CI 1.72-2.05, p < 0.001) of receiving a check. Women giving birth in lower-level public facilities had lower odds of receiving a check (aOR 0.94, 95% CI 0.90-0.98, p = 0.002) compared to those in public hospitals, as did women attended by a nurse/midwife (compared to doctor/nonphysician clinician) (aOR 0.74, 95% CI 0.69-0.78, p < 0.001). This study was limited by the accuracy of the respondent's recall of the provider, timing, and receipt of postpartum checks. The outcome of interest was measured using three slightly different question sets across the 33 included countries.The suboptimal levels of postpartum checks in health facilities in many of the included SSA countries partially reflect the lack of importance given to postpartum care in the global discourse on essential interventions and quality improvement in maternal health. Addressing disparities in access to both facility-based childbirth and good-quality postpartum care in SSA is critical to addressing stalling declines in maternal mortality and morbidity.
P2.03-52 Correlation Between Inflammatory Markers and Oncological Outcomes in Surgically Resected Non-Small Cell Lung Cancer
Authors: R. Waseda, N. Miyahara, T. Moroga, J. Wakahara, H. Mei, L. Yamamoto, N. Imamura, S. Miyahara, T. Shiraishi, A. Iwasaki
Journal: Journal of Thoracic Oncology (2019)
P1.01-109 Phase II Trial of Pemetrexed/Carboplatin/Bevacizumab +/- Atezolizumab in NSCLC Patients That Are EGFR Mutated or Never Smoked
Authors: J.N. Bodor, J. Patel, E. Ross, S. Litwin, J. Treat
Journal: Journal of Thoracic Oncology (2019)
Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death
Authors: Cao Dai Phung, Hanh Thuy Nguyen, Ju Yeon Choi, Thanh Tung Pham, Suman Acharya, Maheshwor Timilshina, Jae-Hoon Chang, Ju-Hyun Kim, Jee-Heon Jeong, Sae Kwang Ku, Han-Gon Choi, Chul Soon Yong, Jong Oh Kim
Journal: Journal of Controlled Release (2019)
Validation of short- and long-term demographic forecasts using the Canadian Cystic Fibrosis Registry
Authors: Vanessa Martelli, Jenna Sykes, Pierre-Régis Burgel, Gil Bellis, Adèle Coriati, Sanja Stanojevic, Anne Louise Stephenson
Journal: European Respiratory Journal (2019)

National cystic fibrosis (CF) data registries track patient characteristics over time and have provided insight into both emerging trends and current clinical needs. In a recent study, Burgel et al . [1] utilised the flow method, a demographic model that predicts future trends in populations, and forecasted a 50% increase in the Western European CF population by 2025, with the adult population experiencing the largest increase. Burgel et al . [2] subsequently used the French registry to validate short-term predictions; however, the accuracy of longer term projections has not been assessed. Based on the results of this study, a model that takes into consideration changing rates over time is needed to accurately estimate future populations <http://bit.ly/35IDhQ0> We thank Cystic Fibrosis Canada for providing access to Canadian CF Registry data for this study, and we thank individuals living with CF and their families for allowing their data to be collected in the CF Registry to be used for clinical research. This work was presented as a poster presented at the North American Cystic Fibrosis Conference, Denver, Colorado, 18–21 October 2018.
P2.01-93 Detection of Giant Cancer-Associated Macrophage-Like Cells After Concurrent Chemoimmunoradiation Is Associated with Poor Survival in NSCLC
Authors: A. Augustyn, D. Adams, J. He, Y. Qiao, T. Xu, Z. Liao, A. Raghavakaimal, K. Gardner, C. Tang, J. Heymach, A. Tsao, S. Lin
Journal: Journal of Thoracic Oncology (2019)
OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
Authors: L. Paz-Ares Rodríguez, D. Spigel, Y. Chen, M. Jove, O. Juan, P. Rich, T. Hayes, V. Gutiérrez Calderón, R. Bernabe, A. Navarro, A. Dowlati, B. Zhang, Y. Moore, T. Wang, N. Nazarenko, S. Ponce, P. Bunn
Journal: Journal of Thoracic Oncology (2019)
A CRISPR-Cas9 Generated Etv6 mutant Mouse Exhibits Decreased Platelet Counts and Functional Platelet Defects
Authors: Leila Noetzli, Jesse W Rowley, Pavel Davizon-Castillo, Greg Kirkpatrick, Katrina J. Ashworth, Sonia Aguila, Christopher C. Porter, Eric Martin Pietras, Andrew S. Weyrich, Jorge Di Paola
Journal: Blood (2017)
MA01.06 Prognostic Factors of Oligometastatic Non-Small Cell Lung Cancer Following Radical Therapy: A Multicenter-Analysis
Authors: M. Patella, I. Opitz, L. Payrard, J.Y. Perentes, T. Krueger, R. Inderbitzi, H. Gelpke, S. Schulte, M. Diezi, M. Gonzalez, W. Weder
Journal: Journal of Thoracic Oncology (2019)
P2.05-16 Diagnostic Value of Concomitant Use of Radial Probe Endobronchial Ultrasound with Guide Sheath and Transbronchial Biopsy in Lung Cancer
Authors: S.C. Lee, E.Y. Kim, M.S. Park, J. Chang, C.H. Han, S.H. Lee
Journal: Journal of Thoracic Oncology (2019)
P2.04-01 Changes of BCR Repertoire Are Predictive Biomarker for the Efficacy of Immune Checkpoint Inhibitor in NSCLC
Authors: K. Azuma, Y. Nakahara, N. Matsuo, H. Ishii, T. Tokito, K. Murotani, T. Hoshino, T. Sasada
Journal: Journal of Thoracic Oncology (2019)
P2.04 NGS-Molecular Characterization of Lung Adenocarcinomas from Hispanic Patients: Level of Evidence for Therapeutic Actionability
Authors: O. Arrieta, R. Gerson, C. Blanco, J. Alexander Meza, A. Silva, S. Rivera Rivera, C. Zuloaga, M. Lazaro, E. Kazakova, A. Villa
Journal: Journal of Thoracic Oncology (2019)
P2.01-95 Updated Data of KRSG 1302 Study: Nedaplatin and Nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer
Authors: F. Ohyanagi, Y. Nagai, T. Kasai, N. Koyama, K. Kobayashi, E. Hoshi, M. Nakayama, K. Mori
Journal: Journal of Thoracic Oncology (2019)
EP1.01-82 10 Years Single Center Experience with Resection of the Superior Vena Cava in Locally Advanced Non-Small Cell Lung Cancer
Authors: M.A. Hoda, T. Klikovits, E. Gschwandtner, K. Sinn, R. Hritcu, W. Klepetko
Journal: Journal of Thoracic Oncology (2019)
EP1.04-29 Khorana Score: A Potential New Biomarker for Real Life Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy
Authors: B. Bjørnhart, K. Hansen, T. Jørgensen, J. Herrstedt, T. Schytte
Journal: Journal of Thoracic Oncology (2019)

PD-L1 tumor proportion score is presently the only biomarker used for selecting incurable NSCLC patients for immune check point inhibition (ICI). Performance score (ECOG) and comorbidities are useful, but no specified guidelines exist in this regard. New objective biomarkers are warranted. Khorana score (KS) is a validated tool used to predict venous thromboembolisms (VTE) in out-patients with cancer prior to chemotherapy. For NSCLC patients undergoing chemotherapy KS has recently been associated with prediction of early mortality and not VTE. KS has not previously been investigated in patients undergoing ICI. Retrospective data from 118 incurable advanced/metastatic NSCLC patients treated with ICI in a single center during the period of September 2015-April 2018 was gathered. Baseline platelet count (PC), leucocyte count (LC), and hemoglobin count (HC) were registered. Baseline body mass index calculations were performed as well as KS (a minimum of KS ≥1 due the primary lung cancer disease). Based on follow-up data Kaplan Meier curve estimates of overall survival (OS) and progression free survival (PFS) were performed. For patient, tumor and treatment characteristics see Table 1. Fourteen percent had known VTE prior to ICI. Two patients died from pulmonary embolisms. KS correlated significantly to OS but not to PFS. A median OS of 18.1 months [CI 12.8-23.4] and 8.4 months [CI 4.3-12-6] was found for groups with KS=1-2 and KS≥3, respectively (log-rank test, p=0.017). Baseline Khorana Score may represent a new clinical applicable prognostic biomarker for incurable NSCLC patients undergoing ICI. A KS ≥3 may be a predictor for early mortality but large prospective studies validating or rejecting this are warranted.
Edoxaban for Cancer-Associated Venous Thromboembolism
Authors: Gary E Raskob, Harry R Büller, Annelise Segers
Journal: New England Journal of Medicine (2018)

93respectively).However, among patients who received sunitinib, grade 3 or 4 treatment-related adverse events were higher among those in the older age group (55% vs. 70%).Our results support an age-independent benefit-risk profile of nivolumab plus ipilimumab, including in elderly patients.Clinical data are lacking to assess any distinctive changes in the cellular immune response to checkpoint inhibitors as a function of age.
P2.04-29 Association of Inflammation Related Genes with Lung Cancer Risk in Moroccan Population
Authors: H. Kaanane, N. Senhaji, H. Berradi, N. Benchakroun, A. Benider, M. Karkouri, H. El Attar, M. Khyatti, S. Nadifi
Journal: Journal of Thoracic Oncology (2019)
Are the 5-hydroxymethylcytosine-based wd-scores really superior over α-fetoprotein for the early diagnosis of hepatocellular carcinoma?
Authors: Yongpeng Chen, Xiao-Yu Lin
Journal: Gut (2019)

We read with interest the recent article by Cai et al 1 describing the development of 5-hydroxymethylcytosine (5hmC)-based wd-scores that have better accuracy in diagnosing early hepatocellular carcinoma (HCC) than does α-fetoprotein (AFP). Although several gene signatures have been published but not used in practice of early HCC diagnosis,2 this study showed the potential application of the 5hmC-based wd scores. However, several concerns remain that need to be clarified.

First, the wd-scores’ cut-off for early diagnosis of HCC, derived by the maximal Youden index and characterised by a sensitivity of 82.7% and a specificity of 76.4%, is suboptimal; this would result in missed diagnosis of early HCC in 17.3% of patients, and the corresponding …
Isolation of Cardiomyocytes Undergoing Mitosis With Complete Cytokinesis
Authors: Hsiao-yun Y. Milliron, Matthew J. Weiland, Eric J. Kort, Stefan Jovinge
Journal: Circulation Research (2019)

Adult human cardiomyocytes do not complete cytokinesis despite passing through the S-phase of the cell cycle. As a result, polyploidization and multinucleation occur. To get a deeper understanding of the mechanisms surrounding division of cardiomyocytes, there is a crucial need for a technique to isolate cardiomyocytes that complete cell division/cytokinesis.Markers of cell cycle progression based on DNA content cannot distinguish between mitotic cardiomyocytes that fail to complete cytokinesis from those cells that undergo true cell division. With the use of molecular beacons (MBs) targeting specific mRNAs, we aimed to identify truly proliferative cardiomyocytes derived from human induced pluripotent stem cells.Fluorescence-activated cell sorting combined with MBs was performed to sort cardiomyocyte populations enriched for mitotic cells. Expressions of cell cycle specific genes were confirmed by means of reverse transcription-quantitative polymerase chain reaction and single-cell RNA sequencing (scRNA-seq) combined with gene signatures of cell cycle progression. We characterized the sorted groups by proliferation assays and time-lapse microscopy which confirmed the proliferative advantage of MB-positive cell populations relative to MB-negative and G2/M populations. Gene expression analysis revealed that the MB-positive cardiomyocyte subpopulation exhibited patterns consistent with the processes of nuclear division, chromosome segregation, and transition from M to G1 phase. The use of dual-MBs targeting CDC20 and SPG20 mRNAs enabled the enrichment of cytokinetic events (CDC20highSPG20high). Interestingly, cells that did not complete cytokinesis and remained binucleated were found to be CDC20lowSPG20high while polyploid cardiomyocytes that replicated DNA but failed to complete karyokinesis were found to be CDC20lowSPG20low.This study demonstrates a novel alternative to existing DNA content-based approaches for sorting cardiomyocytes with true mitotic potential that can be used to study the unique dynamics of cardiomyocyte nuclei during mitosis. Our technique for sorting live cardiomyocytes undergoing cytokinesis would provide a basis for future studies to uncover mechanisms underlying the development and regeneration of heart tissue.
P2.03-53 Immunoproteasome as a Potential Therapeutic Target in Cisplatin-Resistant Small and Non-Small Cell Lung Cancer
Authors: T. Shoji, E. Kikuchi, J. Kikuchi, M. Maeda, Y. Takashima, M. Furuta, H. Takahashi, I. Kinoshita, H. Dosaka-Akita, J. Sakakibara-Konishi, S. Konno
Journal: Journal of Thoracic Oncology (2019)
EP1.17-34 Association Between the Number of Resected Lymph Nodes and Long-Term Survival in N0 Non-Small Cell Lung Cancer: Data from a Chinese Large Cohort
Authors: H. Yang, M. Yang, J. Cai, J. Yang, S. Li, H. Long, J. Fu, L. Zhang, P. Lin, X. Wang, T. Rong
Journal: Journal of Thoracic Oncology (2019)